TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8863301
Drug: Real low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real low-level laser treatment (4 x 6 J per treatment, 20 treatments total)
Study: 2031770
Drug: 10 MU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 MU/m2 of rIFN-alpha, I.M., twice a week for six months
Study: 2031770
Drug: 7.5 MU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 MU/m2 of rIFN-alpha, I.M., twice a week for six months
Study: 2031770
Drug: rIFN-alpha therapy
Normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-alpha therapy (both dosages)
Study: 25239078
Drug: IFN-free therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-free therapy (danoprevir/r 100/100mg, mericitabine 1000 mg, ribavirin 1000/1200 mg)
Study: 25239078
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (danoprevir/r plus PegIFN alfa-2a/ribavirin)
Study: 25239078
Drug: Quad therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quad therapy (danoprevir/r, mericitabine, PegIFN alfa-2a/ribavirin)
Study: 25239078
Drug: IFN-free therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-free therapy
Study: 25239078
Drug: Quad therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quad therapy (Quad 24)
Study: 25239078
Drug: Quad therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quad therapy (Quad 48)
Study: 25239078
Drug: Quad therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quad therapy (partial)
Study: 25239078
Drug: Quad therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quad therapy (null 24)
Study: 22351891
Drug: Treatment failure
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment failure
Study: 16409455
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations of COC
Study: 16129293
Drug: Removal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal of lens epithelial cells (LECs) from the anterior capsule during cataract surgery
Study: 12504937
Drug: Education, age
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education, age at menarche, oral contraceptive use, smoking habits
Study: 9507749
Drug: Ciprofloxacine 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacine 250 mg every 12 hours for 14 days (n = 7)
Study: 9507749
Drug: Trimethoprim 160
Normalized name: trimethoprim 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 160 mg and sulfamethoxazole 800 mg every 12 hours for 14 days (n = 6)
Study: 7896975
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (exposed to a distinctive stimulus before each chemotherapy infusion)
Study: 346617
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg diazepam per day
Study: 23929924
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blockers (losartan or telmisartan)
Study: 19099641
Drug: CD34+ cell
Normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ cell dose > 2 x 10^6/kg
Study: 15684204
Drug: Outpatient care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient care with oral levofloxacin therapy
Study: 15684204
Drug: Hospitalization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospitalization with sequential intravenous and oral levofloxacin therapy
Study: 12850904
Drug: Fixed diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed diazepam tapering regime
Study: 12850904
Drug: Symptom-triggered taper
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-triggered taper method (diazepam only in response to withdrawal symptoms)
Study: 10229153
Drug: Combined Low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Low Intensity Laser Therapy/Phototherapy (CLILT) (660-950 nm; 11 J/cm2; pulsed at 73 Hz)
Study: 7156877
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of 0.1 N HCl (2.5, 5, 10, and 15 ml volumes)
Study: 28419747
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg daprodustat
Study: 28419747
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg daprodustat
Study: 26007314
Drug: High-dose ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ibuprofen (20-10-10 mg/kg/d) for 3 days
Study: 26007314
Drug: Standard-dose ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose ibuprofen (10-5-5 mg/kg/d) for 3 days
Study: 23339736
Drug: Initial maxillary
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial maxillary expansion followed by U-bow activator therapy
Study: 23274323
Drug: Campath 30
Normalized name: Campath 30 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath 30 mg + methylprednisolone 500 mg followed by TAC monotherapy (Group A)
Study: 23274323
Drug: ATG 8
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG 8 mg/kg with TAC + MMF + steroids (Group B)
Study: 19641203
Drug: Vaccine group
Normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine group (10 subjects)
Study: 9071476
Drug: Cyclic estrogen-gestagen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic estrogen-gestagen replacement therapy (ERT)
Study: 8374882
Drug: 30 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes of oral cryotherapy
Study: 8374882
Drug: 60 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 minutes of oral cryotherapy
Study: 12654665
Drug: Daptomycin 4
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 4 mg/kg
Study: 22908174
Drug: Daptomycin 6
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 6 mg/kg
Study: 22908174
Drug: Daptomycin 8
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 8 mg/kg
Study: 27261989
Drug: Music listening
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music listening (ML) program
Study: 25076428
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate (MA) treatment
Study: 20407903
Drug: Contrast-enhanced MRA
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced MRA using Gd-DOTA (intravenous bolus 0.1 mmol/kg)
Study: 16223398
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 1 microg/kg
Study: 7030120
Drug: Disoprofol 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disoprofol 1.2 mg/kg
Study: 7030120
Drug: Disoprofol 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disoprofol 3 mg/kg
Study: 7030120
Drug: Methohexitone 1
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone 1 mg/kg
Study: 7030120
Drug: Methohexitone 2
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone 2 mg/kg
Study: 28303758
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g n‐3 polyunsaturated fatty acids (PUFAs) per day
Study: 28303758
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g olive oil per day (control)
Study: 27089418
Drug: Ginger extract
Normalized name: ginger extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger extract (3g daily for 1 month)
Study: 22515652
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using maxacalcitol lotion (weekdays) and betamethasone butyrate propionate lotion (weekends) for 4 weeks
Study: 22515652
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using maxacalcitol lotion (weekdays) and betamethasone butyrate propionate lotion (weekends) for 8 weeks
Study: 22515652
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with maxacalcitol lotion after combination therapy
Study: 7886461
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with a newly developed boot
Study: 26371
Drug: Inhaled Isoprenaline
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Isoprenaline (1,500 microgram)
Study: 29222947
Drug: Guselkumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (10 mg)
Study: 29222947
Drug: Guselkumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (30 mg)
Study: 29222947
Drug: Guselkumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (100 mg)
Study: 29222947
Drug: Guselkumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (300 mg)
Study: 21409897
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of prunes daily
Study: 21409897
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of prunes
Study: 15979283
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (group I)
Study: 12826854
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with naloxone 0.8 mg
Study: 12826854
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (placebo)
Study: 8263895
Drug: Mailed prescription-refill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mailed prescription-refill reminders
Study: 8263895
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mailed reminders and unit-of-use packaging
Study: 2938986
Drug: Bromocriptine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine treatment to control PRL levels during anesthesia
Study: 2938986
Drug: No bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bromocriptine treatment
Study: 30095660
Drug: Glycopyrrolate (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.005 mg/kg, intramuscular injection)
Study: 30095660
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no glycopyrrolate administration)
Study: 22048442
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of ASA
Study: 20720176
Drug: EX‐FED (beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX‐FED (beverage containing 5 kcal, 0.83 g carbohydrate, 0.37 g protein, and 0.03 g fat)
Study: 18463425
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with levocabastine hydrochloride ophthalmic suspension and pemirolast potassium ophthalmic solution
Study: 18463425
Drug: Single therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single therapy with levocabastine hydrochloride ophthalmic suspension
Study: 16418140
Drug: Metoclopramide IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide IV 0.5 mg 30 minutes before surgery
Study: 16418140
Drug: Ondansetron IV
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron IV 0.1 mg 30 minutes before surgery
Study: 10390744
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg t.i.d. for one year
Study: 1716546
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg hydrocortisone per day
Study: 1716546
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg hydrocortisone per day
Study: 6370437
Drug: Lorazepam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (6 to 2 mg over 4 days)
Study: 6370437
Drug: Chlordiazepoxide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (150 to 50 mg over 4 days)
Study: 22677076
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin (1000 mg twice daily) and pioglitazone (45 mg daily) for 3 months
Study: 20673557
Drug: Atomoxetine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine and behavior therapy
Study: 16344837
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts extended release (MAS XR) 20-60 mg/day
Study: 11122690
Drug: Baseline LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline LDL-C levels as low as 125 mg/dL
Study: 7533484
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone via PCA
Study: 22168750
Drug: Silicone derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone derivative plus onion extract gel (Cybele(®) scagel)
Study: 18633050
Drug: Levobupivacaine 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.2% at 8 mL/h with 3-mL bolus and 15-min lockout (15-min lockout group)
Study: 18633050
Drug: Levobupivacaine 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.2% at 4 mL/h with 8-mL bolus and 30-min lockout (30-min lockout group)
Study: 16170975
Drug: Tooth wipe
Normalized name: Vagisil Wipes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth wipe (Oral‐B Brush‐Ups)
Study: 3125307
Drug: Thyrotropin releasing
Normalized name: Thyrotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin releasing hormone analogue (RX77368)
Study: 27028750
Drug: 3DP fast-melt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3DP fast-melt formulation of levetiracetam
Study: 27028750
Drug: Conventional immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immediate-release tablet of levetiracetam (Keppra(®))
Study: 27028750
Drug: 3DP fast-melt
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3DP fast-melt formulation of levetiracetam under fed conditions
Study: 24030782
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal 0.9% saline infusion)
Study: 14639068
Drug: Continuous renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous renal replacement therapies
Study: 14639068
Drug: Daily dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dialysis
Study: 14639068
Drug: Slow extended
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow extended daily dialysis
Study: 1287614
Drug: Cefaclor AF
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor AF 500 mg twice daily
Study: 1287614
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg three times daily
Study: 3891682
Drug: Proquazone 150
Normalized name: proquazone
DrugBank: Proquazone (DB13649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proquazone 150 mg
Study: 3891682
Drug: Proquazone 75
Normalized name: proquazone
DrugBank: Proquazone (DB13649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proquazone 75 mg
Study: 20220605
Drug: Gua-Sha therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gua-Sha therapy (scraping therapy)
Study: 18560342
Drug: Phytoestrogens therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogens therapy
Study: 9890490
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pentifylline (800 mg) and nicotinic acid (200 mg) daily
Study: 9890490
Drug: Piracetam (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (2.4 g daily)
Study: 7675959
Drug: 0.50 ml
Normalized name: witch hazel 0.50 mL in 1 mL TOPICAL SOLUTION [Medicated Pads]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 ml 95% USP alcohol/kg body weight
Study: 7675959
Drug: 0.75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml 95% USP alcohol/kg body weight
Study: 7675959
Drug: 1.00 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.00 ml 95% USP alcohol/kg body weight
Study: 7675959
Drug: 0.135 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.135 ml 95% USP alcohol/kg body weight (active placebo)
Study: 92511
Drug: 700 CCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 CCA units of purified subunit vaccine
Study: 92511
Drug: 1,400 CCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,400 CCA units of whole-virus vaccine
Study: 92511
Drug: 700 CCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 CCA units of whole-virus vaccine
Study: 26467994
Drug: QoL pathway
Normalized name: Immunoglobulin g1-lambda, anti-(human tissue factor pathway inhibitor (tfpi, extrinsic pathway inhibitor, epi, lipoprotein-associated coagulation inhibitor, laci))
Approvals — FDA: no, EMA: no, PMDA: no
Description: QoL pathway intervention with tailored QoL diagnosis and therapy, including QoL profile and expert report with treatment recommendations.
Study: 23406545
Drug: NK₁ receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK₁ receptor antagonist aprepitant
Study: 14638493
Drug: All resiquimod
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All resiquimod doses
Study: 10651836
Drug: Hyperinsulinemic euglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic euglycemic clamp with infusion of 20 glucose (30% enriched with 13C‐1‐glucose)
Study: 10651836
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with troglitazone
Study: 9079411
Drug: Recombinant follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follicle stimulating hormone (rFSH; Puregon)
Study: 6575025
Drug: Conventional APF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional APF gel
Study: 6575025
Drug: Thixotropic gel
Normalized name: Thyrotropic releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thixotropic gel
Study: 6575025
Drug: Pluronic-based fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pluronic-based fluoride gel
Study: 28167467
Drug: Dermidoc cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermidoc cream
Study: 28167467
Drug: PolymixinB-bacitrin ointment
Normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PolymixinB-bacitrin ointment
Study: 10955337
Drug: Health educational
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health educational and exercise program (6 weekly sessions of 2 hours)
Study: 1362205
Drug: Proglumide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumide (15 mg/day)
Study: 2413282
Drug: Verapamil administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil administered orally (160 mg) before cytostatic treatment
Study: 2413282
Drug: Verapamil administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil administered orally (160 mg) after cytostatic treatment
Study: 14600516
Drug: Simplified maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified maintenance therapy (SMT)
Study: 14600516
Drug: Continued protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued protease inhibitor (PI) therapy
Study: 1824248
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (MTX)
Study: 6850612
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus immunotherapy (Nocardia rubra cell wall skeleton, 400 micrograms, intradermal injection weekly for the first month and monthly thereafter)
Study: 30211721
Drug: Combined mirror
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined mirror and extracorporeal shock wave therapy (ESWT)
Study: 24331545
Drug: Low field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low field magnetic stimulation (LFMS), single 20-minute treatment
Study: 22176629
Drug: Posaconazole 50
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 50 mg
Study: 22176629
Drug: Posaconazole 100
Normalized name: posaconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 100 mg
Study: 22176629
Drug: Posaconazole 200
Normalized name: posaconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 200 mg
Study: 17373918
Drug: Hyperhomocysteinaemia (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperhomocysteinaemia (high homocysteine level >15 micromol/L)
Study: 15829804
Drug: Topical itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical itraconazole 1%
Study: 12102671
Drug: Levetiracetam, 500
Normalized name: LevETIRAcetam, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam, 500 mg, twice daily
Study: 7605860
Drug: Levosulpiride 25
Normalized name: Levosulpiride 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride 25 mg t.d.s. for 4 weeks